Breanna B Greteman, Michael H Tomasson, Amanda R Kahl, Madison M Wahlen, Melissa L Bates, Christopher Strouse, Mary E Charlton
{"title":"Comparison of outcomes by race among a population-based matched sample of multiple myeloma patients.","authors":"Breanna B Greteman, Michael H Tomasson, Amanda R Kahl, Madison M Wahlen, Melissa L Bates, Christopher Strouse, Mary E Charlton","doi":"10.1007/s10552-024-01938-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>It is important to understand racial inequities in multiple myeloma treatment and survival, particularly in the Midwest where clear differences exist in cancer incidence and mortality. Since age and geographic location can greatly impact treatment and prognosis, matching patients on these characteristics can help identify reasons for outcome differences.</p><p><strong>Methods: </strong>Retrospective data from the Iowa Cancer Registry's Surveillance, Epidemiology, and End Results database were analyzed for adult patients diagnosed with first primary MM between 1/1/2010-12/31/2019. Matching procedures matched up to 4 White patients with each Black patient on age and city of residence. Demographic characteristics were compared, and Cox proportional hazards models were built to compare survival.</p><p><strong>Results: </strong>There were 1,845 patients in our overall sample, of which 85 were Black and 1,760 were White. There were 321 patients (74 Black, 247 White) that were matched. Black patients in the overall sample had decreased hazard for MM-specific death compared to White (HR = 0.50, 95% CI (0.43, 0.78)) when controlling for covariates. The decrease in MM-specific death in black patients was not statistically significant compared to matched controls (HR = 0.72, 95% CI (0.41, 1.27)). Treatment differences were not observed for either sample.</p><p><strong>Conclusion: </strong>We found that, despite large racial differences in MM incidence and mortality in Iowa, there are no survival differences when matched on age and city of residence. These data fail to detect large barriers to myeloma treatment in Iowa, and are useful for formulating potential screening and prevention strategies. Future research should also assess results in different geographic areas, investigate survival among older White patients in rural areas, and investigate other potential reasons for mortality differences between Black and White MM patients such as specific treatments received.</p>","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Causes & Control","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10552-024-01938-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: It is important to understand racial inequities in multiple myeloma treatment and survival, particularly in the Midwest where clear differences exist in cancer incidence and mortality. Since age and geographic location can greatly impact treatment and prognosis, matching patients on these characteristics can help identify reasons for outcome differences.
Methods: Retrospective data from the Iowa Cancer Registry's Surveillance, Epidemiology, and End Results database were analyzed for adult patients diagnosed with first primary MM between 1/1/2010-12/31/2019. Matching procedures matched up to 4 White patients with each Black patient on age and city of residence. Demographic characteristics were compared, and Cox proportional hazards models were built to compare survival.
Results: There were 1,845 patients in our overall sample, of which 85 were Black and 1,760 were White. There were 321 patients (74 Black, 247 White) that were matched. Black patients in the overall sample had decreased hazard for MM-specific death compared to White (HR = 0.50, 95% CI (0.43, 0.78)) when controlling for covariates. The decrease in MM-specific death in black patients was not statistically significant compared to matched controls (HR = 0.72, 95% CI (0.41, 1.27)). Treatment differences were not observed for either sample.
Conclusion: We found that, despite large racial differences in MM incidence and mortality in Iowa, there are no survival differences when matched on age and city of residence. These data fail to detect large barriers to myeloma treatment in Iowa, and are useful for formulating potential screening and prevention strategies. Future research should also assess results in different geographic areas, investigate survival among older White patients in rural areas, and investigate other potential reasons for mortality differences between Black and White MM patients such as specific treatments received.
期刊介绍:
Cancer Causes & Control is an international refereed journal that both reports and stimulates new avenues of investigation into the causes, control, and subsequent prevention of cancer. By drawing together related information published currently in a diverse range of biological and medical journals, it has a multidisciplinary and multinational approach.
The scope of the journal includes: variation in cancer distribution within and between populations; factors associated with cancer risk; preventive and therapeutic interventions on a population scale; economic, demographic, and health-policy implications of cancer; and related methodological issues.
The emphasis is on speed of publication. The journal will normally publish within 30 to 60 days of acceptance of manuscripts.
Cancer Causes & Control publishes Original Articles, Reviews, Commentaries, Opinions, Short Communications and Letters to the Editor which will have direct relevance to researchers and practitioners working in epidemiology, medical statistics, cancer biology, health education, medical economics and related fields. The journal also contains significant information for government agencies concerned with cancer research, control and policy.